The effect of cyclandelate in depressed and demented patients: a controlled study in psychogeriatric patients.
In a double-blind clinical trial the effects of the vasodilator drug cyclandelate (in a dose of 1200 mg daily) were studied in a group of patients with depressive illnesses or dementing conditions. The measures used before treatment and after six weeks' treatment were: clinical rating, psychometric tests (Paired Associate Learning Test, Digit Copying Test, Digit Substitution Test, and Serial Learning Test), cortical evoked potentials, the sedation threshold and the Gresham Questionnaire. In the depressive group there were no significant differences in the changes in scores at six weeks in three groups: those who received cyclandelate plus amitriptyline, those who received placebo plus amitriptyline, and those who received neither placebo nor cyclandelate. In the demented group there were significant changes in favour of the placebo on two measures (Digit Copying test, and one component of the auditory evoked response). The results do not support the previously reported views claiming, in a number of studies, a significant improvement in the performance of both demented and normal elderly subjects treated with cyclandelate. The significance of these findings is discussed.
D000368:Aged; D000639:Amitriptyline / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003495:Cyclandelate / Q000627:therapeutic use*; D003704:Dementia / Q000188:drug therapy*; D003863:Depression / Q000188:drug therapy*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007361:Intelligence Tests; D008333:Mandelic Acids / Q000627:therapeutic use*; D010919:Placebos
D008333:Mandelic Acids; D010919:Placebos; D000639:Amitriptyline; D003495:Cyclandelate